Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Spirit Airlines considering bankruptcy filing - WSJ. Port strike ends as dockworkers said to agree on tentative deal with 62% ...
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday after the U.S. Food and Drug Administration removed Eli ...
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...
Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...
Bearish investors decided to classify Hims & Hers Health (HIMS) as an obesity drug supplier. HIMS stock lost 9.6% on Thursday after the U.S. Food and Drug Administration said that GLP-1, made by Eli ...
Exploding sales of prescription weight loss medications have catapulted Novo Nordisk (NVO) and Eli Lilly (LLY) to become the ...
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.
There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...
Nearly 250,000 people in England could be taking Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro within three years ...